Transition to Rebif New Formulation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
To assess patient satisfaction with respect to the incidence of flu-like symptoms (FLS) in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly) to the new formulation of Rebif (RNF) while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurence of flu-like symptoms.
Epistemonikos ID: e7c30a7dad34ab103696d9e4525a655fd5b30847
First added on: May 04, 2024